Swift Biosciences Launches Unique Dual Indexing Kits to Improve Multiplexed Next Generation Sequencing

Food and Healthcare Press Releases Monday April 9, 2018 09:50
ANN ARBOR, Michigan--9 Apr--PRNewswire/InfoQuest
  • New Accel-NGS Unique Dual Indexing Kits minimize read misassignments for higher quality results

Swift Biosciences today announced the launch of its Accel-NGS(R) Unique Dual Indexing Kits , which deliver the power and value of high-throughput multiplexed sequencing while improving the accuracy of low frequency variant calling, such as somatic mutations, in samples such as FFPE and cfDNA.

Multiplexed sequencing is a commonly used technique among clinical research, drug development and clinical services labs utilizing next-generation sequencing (NGS). The Accel-NGS Unique Dual Indexing Kits are an essential addition to NGS workflows, as current tools can suffer from demultiplexing problems caused by index read errors, PCR-induced chimerism associated with multiplexed hybridization capture workflows, and index hopping on patterned flow cells.

Swift's Accel-NGS Unique Dual Indexing Kits, developed in a set of 96 dual indices for both i7 and i5 positions, provide a more scalable and reliable workflow for a range of applications including:
  • Low-frequency somatic variant discovery
  • Formalin-fixed paraffin-embedded analysis
  • Microbial detection in human samples
  • Cell-free DNA analysis

"By directly addressing read misassignments we are providing a more accurate solution which could open up new applications, such as tumor mutation burden profiling," said Candia Brown, Swift's Vice President of Global Marketing.

Key features and benefits of the Accel-NGS Unique Dual Indexing Kits include:
  • Optimized across all Illumina sequencing instruments
  • Improves misassignment rates to less than 0.1 percent
  • Enables multiple applications including whole genome sequencing, whole exome and methylation analysis
  • Compatibility with Swift library prep kits including Accel-NGS 1S, Accel-NGS 2S, and Accel-NGS Methyl-Seq

"Swift's unique dual indices provide higher confidence in calling low frequency variants and maintains data quality as sequencing throughput and multiplexing capability continue to increase," said Laurie Kurihara, PhD, Swift's Vice President of Product Development.

The new indexing kits are specifically designed and compatible for any Illumina platform and are now commercially available.
About Swift Biosciences

Swift Biosciences is the NGS Library Prep company. Based in Ann Arbor, Michigan, the company develops novel library preparation solutions for emerging applications based on next-generation sequencing, including whole genome sequencing, targeted DNA sequencing, and epigenetic analysis. Swift Biosciences' products are designed to help customers analyze challenging biological samples faster, easier, and with greater sensitivity and accuracy, while being compatible with leading instrumentation. Swift Biosciences is the first company to offer library preparation solutions on all three major sequencing platforms, including Pacific Biosciences(R), Illumina(R) and Ion Torrent(TM).

The company opened its doors in February 2010, and its product development enables new applications in multiple industries, including agrigenomics, pharmaceutical, academic, biotechnology, and oncology research fields.

For more information, visit   SwiftBioSci.com and follow Swift Biosciences on Twitter (@SwiftBioSci).

Latest Press Release

The Menarini Group Announces Meropenem/vaborbactam European Marketing Authorization

- Meropenem/vaborbactam approved on 20th November 2018 by the European Commission for clinical use in adult patients with difficult-to-treat infections - The first combination of a carbapenem and a beta-lactamase inhibitor approved for clinical use in...

Merck Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

- FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer - First regulatory designation for M7824 following recent presentation of first clinical data in BTC - BTC is a group of rare, aggressive...

Merck in Agreement With Cyclica for AI-augmented Screening Platform to Expand Research Capabilities

- Agreement to screen discovery and early development compounds using artificial intelligence and computational biophysics - Cloud-based in silico platform that screens small molecules to determine polypharmacological profiles - Evaluation to include...

Vitality-linked Insurers to Get 100 million People 20% More Active by 2025

Building on the results of the largest behaviour change study on physical activity, Vitality and its global network of insurers have collectively committed to improving the health of millions over the next seven years. This is in line with the World...

World Congress of Cardiology Cardiovascular Health 2018 Opens in Dubai

- Professor David Wood, President of the World Heart Federation, welcomes more than 5000 cardiologists, doctors, nurses, and health and policy experts from around the world to Dubai for WCC 2018 at a time when the opportunities for a sustainable impact...

Related Topics